Current hematologic malignancy reports · 2019
What Does Chronic Myeloid Leukaemia Tell Us About Other Leukaemias?
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gale Robert Peter, Apperley Jane
Аннотация
PURPOSE OF REVIEW: Determine if therapy of chronic myeloid leukaemia (CML) is a model for treating other cancers.
RECENT FINDINGS: CML has a relatively homogeneous phenotype and genotype and is caused by one mutation, BCRABL1, in every instance. In contrast, most other leukaemias, haematologic cancers and solid cancer have more heterogeneous phenotypes and extraordinarily greater genotypic diversity and mutational complexity. Lesions learned from treating CML have little applicability to other leukaemias, haematologic cancers or solid cancer.
RECENT FINDINGS: CML has a relatively homogeneous phenotype and genotype and is caused by one mutation, BCRABL1, in every instance. In contrast, most other leukaemias, haematologic cancers and solid cancer have more heterogeneous phenotypes and extraordinarily greater genotypic diversity and mutational complexity. Lesions learned from treating CML have little applicability to other leukaemias, haematologic cancers or solid cancer.